5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>fluorescent proteins allow specific labeling <strong>of</strong> cells and cellular compartments.Furthermore, functional proteins as calcium indicators, channelrhodopsinsor e.g. ferritin are expressed from novel vectors. Here we areproviding an update on the rabies virus vector toolbox, allowing bothretrograde and anterograde labeling <strong>of</strong> neurons, mono synaptic tracing <strong>of</strong>neuronal connections, and studying the function and activity <strong>of</strong> individualneurons.REF 570CMV encephalitis in AIDS patientsSven GRÜTZMEIER 1 , Johan BERGSTRÖM 1 , Eric SANDSTRÖM 1 ,Inger NENNESMO 21 South hospital, Stockholm, SWEDEN; 2 Department <strong>of</strong> Pathology, KarolinskaUniversity Hospital, huddinge, Stockholm, SWEDENA cohort <strong>of</strong> 243 patients with HIV infection was followed 1989 1996 atVenhälsan from diagnosis <strong>of</strong> the infection to death. All were investigatedfor reactivation <strong>of</strong> CMV infection by measuring CMV antigen and/orCMV PCR in the blood and signs <strong>of</strong> CMV encephalitis and CMV retinitis,as well as other opportunistic infections. 221 patients died with CD4count 100 × 106/L. Postmortem brain examinations were performed on 78/221 and 6/22 respectively.Of the 78 patients 70 (90%) had signs <strong>of</strong> reactivated CMV infectionmeasured by blood tests and on morphological examination 43 (55%) hadCMV encephalitis, 16 (21%) toxoplasmosis, 15 (19%) CNS lymphoma,6 (8%) progressive multifocal leukoencephalopathy (PML), 3 (4%) HIVencephalitis and 3 (4%) fungal infection. CMV lesions in the brain wereprimarily found along the walls <strong>of</strong> the ventricles. 15 patients (19%) hadmore than one opportunistic infection. Of the patients with CMV encephalitis90% also had CMV retinitis. Of the six autopsied patients with CD4counts >100 × 106/L the brain was normal in 2 patients, 2 had infarction,1 HIV encephalitis and 1 glioblastoma. CMV encephalitis is the predominantCNS opportunistic infection in this material and also appears to bethe cause <strong>of</strong> death either alone or together with other opportunistic infections.Opportunistic CNS infections are not common if the patients diewith a CD4 count >100 × 106/L. HIV encephalitis is not common in anypatient group, one reason could be that all patients had been treated withzidovudin for their HIV infection.REF 571From rabies virus to new drugs candidatesMonique LAFON, Mireille LAFAGE, Christophe PREHAUDInsitut Pasteur NeuroImmunologie Virale, Paris, FRANCERabies virus is a strictly neurotropic virus which multiplies in the centralnervous system <strong>of</strong> mammals. During the propagation <strong>of</strong> the virus into thenervous system from one neuron to the next order neuron, the infectedneurons rarely encounter apoptosis. Avoiding premature apoptosis can beseen as an adaptive mechanism to facilitate rabies virus propagation fromthe site <strong>of</strong> inoculation by bite, up to the salivary glands where it is excreted.We showed that virulent strains <strong>of</strong> rabies virus, not only avoid prematureapoptosis but also enhance the survival <strong>of</strong> neurons in culture by activatingsurvival and neurogenesis signaling pathways. Rabies virus infectionenhances the regrowth <strong>of</strong> axons <strong>of</strong> adult mouse dorsal root sensory neuronsand promotes neurite outgrowth <strong>of</strong> human neuroblastoma cells (SH SY5Ycells lines). Among the five proteins <strong>of</strong> the virus, we determined that theenvelope glycoprotein, the G protein, drives the neuro survival phenotype.We identified the active polypeptide part <strong>of</strong> the protein and the major roleplayed by its cellular partner, the microtubule associated serine threoninekinase 2, MAST 2. When delivered in cells by a lentivector, the activepolypeptide was observed to favour the healing <strong>of</strong> axons <strong>of</strong> human postmitotic dopaminergic neurons (NT2 N cells) which have been woundedby needle scratches. This new neuro protective compound might foundpromising application in neuro degenerative medicine, demonstrating thatviruses can be a source <strong>of</strong> new drug candidates.REF 572Characterization <strong>of</strong> the Mouse Neuroinvasiveness <strong>of</strong> Selected <strong>European</strong>Strains <strong>of</strong> West Nile VirusStephanie LIM, Penelope KORAKA, Sander VAN BOHEEMEN, JoukeROOSE, Dick JAARSMA, David VAN DE VIJVER, AlbertOSTERHAUS, Byron MARTINAErasmus Medical Centre, Rotterdam, THE NETHERLANDSWest Nile virus (WNV) has caused outbreaks and sporadic infections inCentral, Eastern and Mediterranean Europe for over 45 years. Most strainsresponsible for the <strong>European</strong> and Mediterranean basin outbreaks are classifiedas lineage 1. In recent years, WNV strains belonging to lineage 1and 2 have been causing outbreaks <strong>of</strong> neuroinvasive disease in humans incountries such as Italy, Hungary and Greece, while mass mortality amongbirds was not reported. This study characterizes three <strong>European</strong> strains<strong>of</strong> WNV isolated in Italy (FIN and Ita09) and Hungary (578/10) in terms<strong>of</strong> in vitro replication kinetics on neuroblastoma cells, LD50 values inC57BL/6 mice, median day mortality, cumulative mortality, concentration<strong>of</strong> virus in the brain and spinal cord, and the response to infectionin the brain. Overall, the results indicate that strains circulating in Europebelonging to both lineage 1 and 2 are highly virulent and that Ita09 and578/10 are more neurovirulent compared to the FIN strain.REF 573Association between grey matter volumes and Herpes Simplex VirusType 1 specific humoral immunity in Alzheimer’s diseaseRoberta MANCUSO 1 , Francesca BAGLIO 2 , Monia CABINIO 2,4 , ElenaCALABRESE 3 , Ambra HERNIS 1 , Milena ZANZOTTERA 1 , FrancaGUERINI 1 , Raffaello NEMNI 3,4 , Mario CLERICI 1,41 Laboratory <strong>of</strong> Molecular Medicine and Biotechnology, Don GnocchiFoundation IRCCS, Milan, ITALY; 2 Magnetic Resonance Laboratory, DonC. Gnocchi Foundation IRCCS, Milan, ITALY; 3 Dept. Neurorehabilitation,Don C. Gnocchi Foundation IRCCS, Milan, ITALY; 4 Department <strong>of</strong>Physiopathology and Transplantation, University <strong>of</strong> Milan, Milan, ITALYBackground and aims: HSV1 is suspected to be a risk factor for Alzheimerdisease (AD): it can infect the regions <strong>of</strong> the central nervous systemwhich are affected by AD associated pathological changes (hippocampal,temporal region). Therefore we evaluated the possible correlations betweenHSV1 humoral immunity and cortical grey matter (GM) volumein AD patients. Materials and methods: 134 subjects were enrolled inthe study: 83 AD (mean age 77+7 yrs; 50 M) (NINCDSADRDA criteria/DSMIV R) and 51 healthy controls (HC) age and sex matched. Patientsunderwent a Mini Mental State Evaluation (MMSE) and HSV1 IgG antibodies(Ab index) were tested in serum by ELISA test. 44 AD HSV1seropositive patients underwent a Magnetic Resonance Imaging (MRI)examination to investigate cortical gray matter (GM) volume (Voxel BasedMorphometry study). ApoE genotyping was also obtained. To highlightthe correlation between GM and HSV1 values, a regression analysis wasperformed on MRI data including for each subject GM maps and HSVantibody values. Statistical analyses were performed on SPM8 s<strong>of</strong>tware.Results: Seroprevalence and Ab titers were comparable in two groups.High HSV1 titers (Ab index >75 ◦ percentile) were present in 35.8% <strong>of</strong> ADvs. 16% <strong>of</strong> HC (p=0.024). Notably, HSV1 Ab titers were positively correlatedwith cortical volume bilaterally in temporal and orbit<strong>of</strong>rontal cortex(clusters corrected FWE
5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>REF 574Possible Involvement <strong>of</strong> Beta herpesviruses HHV 6 and HHV 7 andparvovirus B19 Infection in the Development <strong>of</strong> EncephalopathyModra MUROVSKA 1 , Svetlana CHAPENKO 1 , Santa RASA 1 , SilvijaROGA 2,3 , Zaiga NORA KRUKLE 11 A.Kirchenstein Institute <strong>of</strong> Microbiology and <strong>Virology</strong>, Riga Stradins University,Riga, LATVIA; 2 Chair <strong>of</strong> Pathology, Riga Stradins University,Riga, LATVIA; 3 Riga 1st Hospital, Riga, LATVIAEncephalopathy is a syndrome <strong>of</strong> global brain dysfunction with unclearaetiology. HHV 6 and HHV 7 are neurotropic viruses associated with awide variety <strong>of</strong> neurologic disorders. Involvement <strong>of</strong> B19 in neurologicpathologies is rarely reported.Our study aims to investigate the frequency <strong>of</strong> B19 and HHV 6, HHV7 infection markers in meningeal and brain tissues <strong>of</strong> individuals withunspecified encephalopathy. 34 individuals with and 34 without signs <strong>of</strong>encephalopathy were enrolled in the study. nPCR was used to detect B19,HHV 6 and HHV 7 DNA in autopsy specimens (dura and pia mater, braintissue) and to define HHV 6 variant. Significantly higher frequency <strong>of</strong> viralDNAs detection was found in specimens from individuals with encephalopathycomparing to the control group (32/34 vs. 25/34, p=0.044). Nodifference was detected regarding the presence <strong>of</strong> B19 (17/34 vs. 9/34,p=0.079) and HHV 7 DNA (21/34 vs. 21/34). Frequency <strong>of</strong> single HHV6 infection (8/34 vs. 1/34, p=0.027) and co infections (29/34 vs. 14/34,p=0.0003) was higher in encephalopathy specimens, single HHV 7 infectionin control group’s samples (2/34 vs. 9/34, p=0.044). Frequency <strong>of</strong> B19infection/co infection was higher in pia mater, HHV 6 in brain tissue andpia mater, HHV 7 in brain tissue specimens <strong>of</strong> individuals with encephalopathy.In all HHV 6 positive samples HHV 6B variant was recognized.Meningeal and brain tissues are sites <strong>of</strong> B19, HHV 6, HHV 7 persistency.Simultaneous study <strong>of</strong> these viral infections and their activity stages arerequired to identify the relation with the development <strong>of</strong> encephalopathy.REF 575Identification <strong>of</strong> viral determinants involved in Borna Disease Virusinterference with human neurogenesisChloé SCORDEL 1 , Marielle COCHET 1 , Marion SZELECHOWSKI 2 ,Daniel GONZALEZ DUNIA 2 , Marc ELOIT 1 , Muriel COULPIER 11 UMR1161 de vi<strong>rologie</strong>, ENVA INRA ANSES, Maisons Alfort, FRANCE;2 INSERM, U1043, Toulouse, FRANCEBorna disease virus (BDV) is a neurotropic virus causing neurologicaldisorders and encephalitis in horse and sheep. BDV antigens can be foundin human and the infection could be associated with the development <strong>of</strong>psychiatric disorders. By using human Neural Progenitor Cells (hNPCs)in culture, we previously demonstrated that BDV interferes with humanneurogenesis by inducing the death <strong>of</strong> newly formed neurons. Our researchnow focuses on the identification <strong>of</strong> viral determinants responsible for thisinterference. We used lentiviral vectors containing genes encoding 3 viralproteins, the X protein, the nucleoprotein (N), and the phosphoprotein (P)and demonstrated that these 3 proteins neither interfere with hNPCs proliferationnor with atroglial differentiation. Likewise, the X protein does notimpair neuronal differentiation. On the contrary, N and P strongly impairneuronal differentiation, resulting in a 25 and 50% decrease in the number<strong>of</strong> neurons, respectively. No death was observed in differentiated cellsexpressing N and P, indicating that the two proteins inhibit neuronal differentiationrather than trigger neuronal apoptosis. We next focused on thecharacterization <strong>of</strong> the molecular pathways impaired by P. We found analteration <strong>of</strong> two proteins known to be involved in neurogenesis: the transcriptionalrepressor REST was up regulated and one <strong>of</strong> its targets, SCG10,was down regulated. Our results demonstrate that the phosphoprotein <strong>of</strong>BDV specifically impairs neurogenesis. We are currently pursuing thecharacterization <strong>of</strong> the cellular and molecular mechanisms altered.REF 576Human endogenous retroviruses <strong>of</strong> the HERV W family are upregulatedby the JC polyomavirus in human astrocytesElena ULERI 1 , Elena ULERI 1 , Serra CATERINA 1 , GiuseppeMAMELI 1 , Ilker K SARIYER 2 , Kamel KHALILI 2 , Antonina DOLEI 11 Department <strong>of</strong> Biomedical Sciences, University <strong>of</strong> Sassari, Sassari,ITALY; 2 Department <strong>of</strong> Neuroscience, Center for Neurovirology, TempleUniversity School <strong>of</strong> Medicine, Philadelphia, USAThe ubiquitous JCV polyomavirus causes progressive multifocal leukoencephalopathyin patients severely immunosuppressed or with autoimmunediseases treated with immunosuppressive antibodies. In most <strong>of</strong> thesediseases, upregulation <strong>of</strong> HERV W/MSRV/syncytin 1 endogenous retroviruseswas reported. Since the HERV W/MSRV/syncytin 1 are potentiallyneuropathogenic, we wondered about their interactions with JCV, thatcould contribute to neurodegeneration. Thus, human primary fetal astrocytesand the U87MG cell line were infected by JCV or transfected withexpression plasmids carrying early or late JCV genes, to monitor HERVW/MSRV/syncytin 1 expression, or that <strong>of</strong> constructs carrying the syncytin1 promoter. Infection by JCV upregulated both MSRV like and syncytinenv transcripts. Transient transfection showed that both JCV early and lateproteins stimulate the transcription <strong>of</strong> HERV W/MSRV/syncytin 1 envgenes. As for the HERV W promoter activity in presence <strong>of</strong> JCV proteins,gene reporter experiments with constructs carrying the full length syncytin1 promoter, or promoter deletion mutants, co transfected with JCVearly or late plasmids were carried out. Data indicate that the full lengthpromoter is upregulated by both JCV proteins. Deletion <strong>of</strong> the upstream(cellular) regulatory region indicate that the stimulatory effect lies on the5 ′ LTR (viral) moiety. Due to the identities between the 5 ′ LTR <strong>of</strong> MSRVand syncytin 1, it is likely that up regulation by JCV antigens <strong>of</strong> bothMSRV and syncytin 1 requires mainly the viral moiety <strong>of</strong> their promoters.S280 Vi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013
- Page 3 and 4:
Contents5 th European Congress of V
- Page 5 and 6:
i r o l o g i eList of Keynote Spea
- Page 7 and 8:
i r o l o g i eList of Chairpersons
- Page 9 and 10:
i r o l o g i eWelcomeWelcome to th
- Page 11 and 12:
5 th European Congress of VirologyY
- Page 13 and 14:
i r o l o g i eExhibitorsThe indust
- Page 15:
i r o l o g i eFacilities for the 5
- Page 18 and 19:
i r o l o g i eGeneral Information
- Page 20 and 21:
PROGRAMME AT A GLANCEWednesday 11th
- Page 22 and 23:
5 th European Congress of VirologyW
- Page 24 and 25:
5 th European Congress of VirologyW
- Page 26 and 27:
5 th European Congress of VirologyW
- Page 28 and 29:
5 th European Congress of VirologyW
- Page 30 and 31:
5 th European Congress of VirologyW
- Page 32 and 33:
Scientific Programme -Saturday 14 t
- Page 34 and 35:
5 th European Congress of Virology1
- Page 36 and 37:
5 th European Congress of VirologyW
- Page 38 and 39:
5 th European Congress of VirologyW
- Page 40 and 41:
5 th European Congress of VirologyW
- Page 42 and 43:
5 th European Congress of VirologyW
- Page 44 and 45:
5 th European Congress of VirologyW
- Page 46 and 47:
5 th European Congress of VirologyW
- Page 48 and 49:
5 th European Congress of VirologyT
- Page 50 and 51:
5 th European Congress of VirologyT
- Page 52 and 53:
5 th European Congress of VirologyT
- Page 54 and 55:
5 th European Congress of VirologyR
- Page 56 and 57:
5 th European Congress of VirologyR
- Page 58 and 59:
5 th European Congress of Virologyw
- Page 60 and 61:
5 th European Congress of VirologyT
- Page 62 and 63:
5 th European Congress of VirologyR
- Page 64 and 65:
5 th European Congress of Virologyt
- Page 66 and 67:
5 th European Congress of VirologyR
- Page 68 and 69:
5 th European Congress of VirologyT
- Page 70 and 71:
5 th European Congress of VirologyA
- Page 72 and 73:
5 th European Congress of Virologyp
- Page 74 and 75:
5 th European Congress of VirologyR
- Page 76 and 77:
5 th European Congress of VirologyF
- Page 78 and 79:
5 th European Congress of VirologyF
- Page 80 and 81:
5 th European Congress of Virologyc
- Page 82 and 83:
5 th European Congress of VirologyF
- Page 84 and 85:
5 th European Congress of VirologyF
- Page 86 and 87:
5 th European Congress of Virologyt
- Page 88 and 89:
5 th European Congress of VirologyH
- Page 90 and 91:
5 th European Congress of VirologyF
- Page 92 and 93:
5 th European Congress of VirologyR
- Page 94 and 95:
5 th European Congress of VirologyR
- Page 96 and 97:
5 th European Congress of VirologyS
- Page 98 and 99:
5 th European Congress of VirologyS
- Page 100 and 101:
5 th European Congress of VirologyS
- Page 102 and 103:
5 th European Congress of VirologyS
- Page 104 and 105:
5 th European Congress of VirologyA
- Page 106 and 107:
5 th European Congress of Virology1
- Page 108 and 109:
5 th European Congress of Virology1
- Page 110 and 111:
5 th European Congress of VirologyS
- Page 112 and 113:
5 th European Congress of VirologyS
- Page 114 and 115:
5 th European Congress of VirologyS
- Page 116 and 117:
5 th European Congress of VirologyS
- Page 118 and 119:
Virologie 2013, 17 (supplément 2)
- Page 120 and 121:
5 th European Congress of VirologyA
- Page 122 and 123:
5 th European Congress of Virology0
- Page 124 and 125:
5 th European Congress of Virology0
- Page 126 and 127:
5 th European Congress of VirologyH
- Page 128 and 129:
5 th European Congress of Virologys
- Page 130 and 131:
5 th European Congress of Virology0
- Page 132 and 133:
5 th European Congress of Virologyf
- Page 134 and 135:
5 th European Congress of VirologyE
- Page 136 and 137:
5 th European Congress of Virologyt
- Page 138 and 139:
5 th European Congress of VirologyA
- Page 140 and 141:
5 th European Congress of Virologyp
- Page 142 and 143:
5 th European Congress of Virology0
- Page 144 and 145:
5 th European Congress of Virologyi
- Page 146 and 147:
5 th European Congress of Virologyr
- Page 148 and 149:
5 th European Congress of Virologyi
- Page 150 and 151:
5 th European Congress of Virologyp
- Page 152 and 153:
5 th European Congress of Virology3
- Page 154 and 155:
5 th European Congress of VirologyR
- Page 156 and 157:
5 th European Congress of Virology0
- Page 158 and 159:
5 th European Congress of Virologyt
- Page 160 and 161:
5 th European Congress of VirologyB
- Page 162 and 163:
5 th European Congress of Virologyr
- Page 164 and 165:
5 th European Congress of VirologyR
- Page 166 and 167:
5 th European Congress of Virologyi
- Page 168 and 169:
5 th European Congress of VirologyI
- Page 170 and 171:
5 th European Congress of Virologyf
- Page 172 and 173:
5 th European Congress of Virologya
- Page 174 and 175:
5 th European Congress of VirologyS
- Page 176 and 177:
5 th European Congress of Virology1
- Page 178 and 179:
5 th European Congress of Virologyt
- Page 180 and 181:
5 th European Congress of VirologyV
- Page 182 and 183:
5 th European Congress of Virologyc
- Page 184 and 185:
5 th European Congress of Virologyw
- Page 186 and 187:
5 th European Congress of Virologyt
- Page 188 and 189:
5 th European Congress of Virologya
- Page 190 and 191:
5 th European Congress of VirologyA
- Page 192 and 193:
5 th European Congress of Virologyn
- Page 194 and 195:
5 th European Congress of Virologyi
- Page 196 and 197:
5 th European Congress of Virologyw
- Page 198 and 199:
5 th European Congress of VirologyT
- Page 200 and 201:
5 th European Congress of Virology(
- Page 202 and 203:
5 th European Congress of Virologya
- Page 204 and 205:
5 th European Congress of Virology1
- Page 206 and 207:
5 th European Congress of Virologyo
- Page 208 and 209:
5 th European Congress of VirologyI
- Page 210 and 211:
5 th European Congress of VirologyR
- Page 212 and 213:
5 th European Congress of Virologyw
- Page 214 and 215:
5 th European Congress of Virologyt
- Page 216 and 217:
5 th European Congress of Virologya
- Page 218 and 219:
5 th European Congress of Virologyp
- Page 220 and 221:
5 th European Congress of Virologya
- Page 222 and 223:
5 th European Congress of Virology(
- Page 224 and 225:
5 th European Congress of Virologyt
- Page 226 and 227:
5 th European Congress of Virologyn
- Page 228 and 229:
5 th European Congress of Virologyi
- Page 230 and 231: 5 th European Congress of Virologyo
- Page 232 and 233: 5 th European Congress of Virology2
- Page 234 and 235: 5 th European Congress of VirologyR
- Page 236 and 237: 5 th European Congress of Virology7
- Page 238 and 239: 5 th European Congress of VirologyR
- Page 240 and 241: 5 th European Congress of VirologyR
- Page 242 and 243: 5 th European Congress of Virologya
- Page 244 and 245: 5 th European Congress of Virologyc
- Page 246 and 247: 5 th European Congress of Virologya
- Page 248 and 249: 5 th European Congress of Virologyh
- Page 250 and 251: 5 th European Congress of Virology6
- Page 252 and 253: 5 th European Congress of VirologyC
- Page 254 and 255: 5 th European Congress of VirologyM
- Page 256 and 257: 5 th European Congress of Virologyi
- Page 258 and 259: 5 th European Congress of Virology2
- Page 260 and 261: 5 th European Congress of Virologyf
- Page 262 and 263: 5 th European Congress of VirologyR
- Page 264 and 265: 5 th European Congress of Virologyw
- Page 266 and 267: 5 th European Congress of VirologyM
- Page 268 and 269: 5 th European Congress of VirologyI
- Page 270 and 271: 5 th European Congress of Virologyp
- Page 272 and 273: 5 th European Congress of Virologyu
- Page 274 and 275: 5 th European Congress of VirologyO
- Page 276 and 277: 5 th European Congress of Virologys
- Page 278 and 279: 5 th European Congress of Virology2
- Page 282 and 283: 5 th European Congress of Virology2
- Page 284 and 285: 5 th European Congress of VirologyA
- Page 286 and 287: 5 th European Congress of VirologyI
- Page 288 and 289: 5 th European Congress of VirologyB
- Page 290 and 291: 5 th European Congress of VirologyD
- Page 292 and 293: 5 th European Congress of VirologyG
- Page 294 and 295: 5 th European Congress of VirologyJ
- Page 296 and 297: 5 th European Congress of VirologyL
- Page 298 and 299: 5 th European Congress of VirologyN
- Page 300 and 301: 5 th European Congress of VirologyR
- Page 302 and 303: 5 th European Congress of VirologyS
- Page 304 and 305: 5 th European Congress of VirologyW